5 results on '"Ramachandran, Raja"'
Search Results
2. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis.
- Author
-
Rathi M, Goyal A, Jaryal A, Sharma A, Gupta PK, Ramachandran R, Kumar V, Kohli HS, Sakhuja V, Jha V, and Gupta KL
- Subjects
- Administration, Intravenous, Administration, Oral, Adolescent, Adult, Anti-Inflammatory Agents therapeutic use, Azathioprine therapeutic use, Cyclophosphamide adverse effects, Cyclophosphamide economics, Drug Costs, Female, Gastrointestinal Diseases chemically induced, Humans, Immunosuppressive Agents adverse effects, Immunosuppressive Agents economics, Induction Chemotherapy adverse effects, Maintenance Chemotherapy, Male, Methylprednisolone therapeutic use, Mycophenolic Acid adverse effects, Mycophenolic Acid economics, Severity of Illness Index, Treatment Outcome, Young Adult, Cyclophosphamide administration & dosage, Immunosuppressive Agents administration & dosage, Induction Chemotherapy methods, Lupus Nephritis drug therapy, Mycophenolic Acid administration & dosage
- Abstract
No previous study has compared mycophenolate mofetil (MMF) with low-dose cyclophosphamide (CYC) in the treatment of lupus nephritis (LN). To do so, we recruited patients with LN (class III, IV, or V) and randomized them to receive either low-dose CYC or oral MMF. Those with crescentic LN, a serum creatinine over 265 μmol/l, and neurological or pulmonary lupus were excluded. MMF was prescribed at daily doses of 1.5-3 g for 24 weeks, while CYC was administered as six fortnightly infusions of 500 mg each. All patients received three methylprednisolone injections, followed by oral corticosteroids. Maintenance therapy with azathioprine and low-dose corticosteroid was started at end of induction therapy. The primary end point was treatment response at 24 weeks, while secondary end points were complete remission, Systemic Lupus Erythematosus Disease Activity Index and adverse events. Of the 173 patients recruited, 100 were equally randomized to receive either CYC or MMF. Baseline characteristics were similar, except for higher 24 h proteinuria in the CYC group. At 24 weeks, 37 patients in each group achieved the primary end point. The complete remission rate was 50% in CYC and 54% in MMF group. Gastrointestinal symptoms were significantly more frequent in patients receiving MMF (52 vs. 4%). However, other adverse events were similar. Thus, low-dose intravenous CYC is comparable in safety and efficacy to oral MMF in the induction treatment of less severe LN., (Copyright © 2015 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
3. Tacrolimus therapy in adult-onset steroid-resistant nephrotic syndrome due to a focal segmental glomerulosclerosis single-center experience.
- Author
-
Ramachandran R, Kumar V, Rathi M, Nada R, Jha V, Gupta KL, Sakhuja V, and Kohli HS
- Subjects
- Adolescent, Adult, Creatinine blood, Female, Humans, Male, Middle Aged, Nephrotic Syndrome etiology, Prednisolone therapeutic use, Prospective Studies, Recurrence, Remission Induction, Young Adult, Drug Resistance drug effects, Glomerulosclerosis, Focal Segmental complications, Immunosuppressive Agents therapeutic use, Nephrotic Syndrome drug therapy, Steroids pharmacology, Tacrolimus therapeutic use
- Abstract
Introduction: Management of adults with steroid-resistant (SR) nephrotic syndrome due to focal segmental glomerulosclerosis (FSGS) is a challenging task. Is tacrolimus (TAC) effective in this situation without serious adverse effects? This prospective study was done to answer this question., Materials and Methods: In patients with SR nephrotic syndrome due to FSGS, oral TAC (0.1 mg/kg/day) was started targeting a trough level of 5-10 ng/mL along with oral prednisolone (0.15 mg/kg/day) for 48 weeks. In patients with complete remission (CR), TAC dose was reduced to a target of 3-6 ng/mL whereas in partial responders, TAC trough levels were kept at 5-10 ng/mL. TAC was discontinued in those with no remission at 24 weeks and was deemed TAC resistant. Outcome, namely CR and partial remission (PR), was assessed at the end of 24 and 48 weeks. All patients were prospectively followed for 60 weeks. Relapses after CR or PR were recorded; adverse effects, namely nephrotoxicity (>25% rise in creatinine), cosmetic effects, infections and hyperglycemia, were recorded every month., Results: A total of 44 SR-FSGS [not otherwise specified 33 (75%), tip lesion 03 (6.8%) and cellular variant 8 (18.1%)] were analyzed. Mean age was 25.16 ± 8.26 (18-51) years. Of 44 patients, CR and PR were achieved in 17 (38.6%) and 06 (13.6%) patients, respectively. TAC resistance was seen in 21 (47.7%) patients. Time taken to achieve remission was 15.2 ± 6 weeks. Five (21.7%) patients with CR had relapse on tapering the dose and seven (30.4%) after stopping TAC. Reversible nephrotoxicity was seen in seven (15.9%) and irreversible in four patients (9%). TAC-related diarrhea was the problem in 10 (22.7%), and infections were seen in 19 patients (43.1%). Impaired fasting glucose and diabetes mellitus were seen in 10 patients (22.7%)., Conclusion: TAC is an effective agent in the management of SR-FSGS. However, strict renal function and blood sugar monitoring is required due to its potential nephrotoxicity and diabetogenic potential., (© The Author 2014. Published by Oxford University Press on behalf of ERAEDTA. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
4. Outcomes of primary membranous nephropathy refractory to immunosuppressants.
- Author
-
Nayak, Saurabh, Chauhan, Prabhat, Jha, Vivekanand, Ramachandran, Raja, and Bose, Bhadran
- Subjects
KIDNEY diseases ,IMMUNOSUPPRESSIVE agents ,REFRACTORY materials ,CHRONIC kidney failure ,KIDNEY glomerulus diseases - Abstract
This article discusses the outcomes of primary membranous nephropathy (PMN) patients who are refractory to immunosuppressants. PMN is a common cause of adult-onset nephrotic syndrome, and current guidelines recommend immunosuppressive therapy. However, a significant proportion of patients do not respond to initial treatment and require rescue therapy. The article presents a systematic review of 18 observational studies that analyzed different rescue therapies for refractory membranous nephropathy. The findings suggest that rituximab, adrenocorticotrophic hormone, and obinutuzumab show promising results, but there is no clear winner. The choice of treatment should be based on individual patient characteristics and side effect profiles. Further controlled studies are needed to investigate these agents. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
5. Usefulness of mycophenolate mofetil in Indian patients with C3 glomerulopathy.
- Author
-
Bharati, Joyita, Tiewsoh, Karalanglin, Kumar, Ashwani, Nada, Ritambhra, Rathi, Manish, Gupta, Krishan Lal, Kohli, Harbir Singh, Jha, Vivekananda, and Ramachandran, Raja
- Subjects
MYCOPHENOLIC acid ,CHRONIC kidney failure ,NEPHROTIC syndrome ,MEDICAL records ,IMMUNOSUPPRESSIVE agents - Abstract
Background C3 glomerulopathy (C3G) is a heterogeneous disease caused by alternative complement pathway abnormalities without any standardized treatment. An immunosuppressive agent, mycophenolate mofetil (MMF), has been recently shown to be useful in treating C3G, mainly in studies from the west. We report the clinical outcome of 17 Indian C3G patients treated with MMF with or without steroids. Methods The clinical and histology details of the C3G patients treated with MMF for at least 6 months with a follow-up of at least 12 months were retrieved from the medical records of our center. Results The median serum creatinine and proteinuria at presentation were 0.8 mg/dL and 3.7 g/day, respectively, with the majority (88.2%) presenting as nephrotic syndrome. The mean dose of MMF was 1.65 (±0.56) g/day, and the median duration of MMF therapy was 18 months. Two-thirds (64%) of the patients responded to the treatment, with complete remission in 4 (23%) and partial remission in 7 (41%) (median time: 9 months). Three patients progressed to end-stage renal disease (ESRD) on follow-up. Of the three patients, one (33%) had an initial response in proteinuria to MMF but did not respond after a relapse and subsequently progressed to ESRD and two (67%) other patients were nonresponsive to MMF from the start of the therapy. Conclusion Despite a small sample size and lack of a control arm, this study describes the effectiveness of MMF in treating C3G patients from Asia and forms a basis for future randomized trials. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.